Compare SRTA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | VNDA |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.2M | 425.5M |
| IPO Year | N/A | 2006 |
| Metric | SRTA | VNDA |
|---|---|---|
| Price | $4.92 | $8.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.63 | ★ $13.13 |
| AVG Volume (30 Days) | 787.6K | ★ 2.6M |
| Earning Date | 02-15-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $268,618,000.00 | $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | $24.64 | $21.57 |
| P/E Ratio | $10.29 | ★ N/A |
| Revenue Growth | ★ 70.11 | 11.12 |
| 52 Week Low | $2.35 | $3.81 |
| 52 Week High | $6.02 | $9.60 |
| Indicator | SRTA | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 68.93 |
| Support Level | N/A | $6.87 |
| Resistance Level | N/A | $9.60 |
| Average True Range (ATR) | 0.00 | 0.49 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 0.00 | 60.87 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement, and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.